secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001323885-22-000113
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q3 revenue $83.2M (+18.1% YoY); net loss $0.27/share; guides FY2022 rev ~$328-333M
--------------------------------------------------------------------------------

- Revenue $83.2M, up 18.1% YoY (19.8% constant currency). US revenue $69.8M (+21.3%).
- Gross margin flat at 74.1%; operating loss $10.7M vs income $98.7M in Q3 2021 (includes non-recurring items).
- Adjusted EBITDA negative $0.7M vs positive $0.7M last year; adjusted EPS loss $0.27 vs $0.23.
- FY 2022 guidance: revenue ~$328-333M (20-21% growth), adjusted EBITDA loss ~$4M, adjusted loss per share ~$1.10-$1.12.
- Growth driven by cryoSPHERE pain management, AtriClip Flex·V, and EnCompass clamp; international growth in Australia and Japan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388522000113/0001323885-22-000113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388522000113/atrc-20221101.htm
  HTML page:      https://secwatch.observer/filing/0001323885-22-000113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer